Evidence map›Paper›PMID 41132740›Full record

ArticleRSC advances2025

Desferrioxamine mesylate encapsulated novel chitosan based polymeric nanocomposites: insights into drug interaction, biocompatibility, cytotoxicity, cell permeability, antioxidant and controlled release properties.

A K D V K Wimalasiri, P Kalansuriya, B P Espósito, T A Pereira, Yongmei Zhao, J C Godevithana, K Siriwardana, M Mohotti, E Lacerda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A K D V K WimalasiriDepartment of Biochemistry, Faculty of Medicine, University of Ruhuna Sri Lanka p_kalansuriya@med.ruh.ac.lk.
P KalansuriyaDepartment of Biochemistry, Faculty of Medicine, University of Ruhuna Sri Lanka p_kalansuriya@med.ruh.ac.lk.ORCID https://orcid.org/0000-0003-3502-9287
B P EspósitoDepartment of Fundamental Chemistry, University of São Paulo São Paulo Brazil.
T A PereiraDepartment of Fundamental Chemistry, University of São Paulo São Paulo Brazil.
Yongmei ZhaoSchool of Pharmacy, Nantong University China.
J C GodevithanaDepartment of Community Medicine, Faculty of Medicine, University of Ruhuna Sri Lanka.
K SiriwardanaDepartment of Chemistry, Faculty of Science, University of Ruhuna Sri Lanka.
M MohottiDepartment of Haematology, National Hospital Galle Karapitiya Sri Lanka.
E LacerdaDepartment of Fundamental Chemistry, University of São Paulo São Paulo Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desferrioxamine (DFO) is a clinically established iron chelator used to manage iron overload in transfusion-dependent thalassemia patients. Despite its efficacy, DFO's poor cellular permeability and burst release profile limit its application to subcutaneous administration, precluding its use as an oral formulation. To address these limitations, DFO was encapsulated in a nanocomposite matrix composed of chitosan (CTS), polyethylene oxide (PEO), ethyl cellulose (EC), and tripolyphosphate (TPP). The resulting nanocomposites were comprehensively characterized using scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS), particle size analysis (PSA), and Fourier-transform infrared spectroscopy (FT-IR). The

Identifiers

PMID41132740
PMCPMC12542970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.